{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:12:16Z","timestamp":1772554336255,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aim of this study was to estimate the Italian burden of incident breast cancer (BC) by subtypes, according to the distribution of hormonal receptor (HR) status and expression of human epidermal growth factor 2 (HER2).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Female breast cancers incidence in the Romagna Unit of the Emilia-Romagna registry (<jats:italic>n<\/jats:italic>. 10,711) were grouped into: HR+\u2009\/HER2\u2013, HR+\u2009\/HER2+\u2009, HR\u2013\/HER2+\u2009, HR\u2013\/HER2\u2013 and missing, and by age:\u2009&lt;\u200950, 50\u201369 and 70+\u2009years. Data were compared with other published Italian population-bases series before using them for national estimates. We used national and regional numbers of expected breast cancers published by the Italian network of cancer registries considering the age- and geographic-specific variation of the Italian population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 70.7% of incident BC cases are expected to be HR+\u2009\/HER2-, 8.5% HR+\u2009\/HER2+\u2009, 7.5% HR-\/HER2-, 4.1% HR-\/HER2+\u2009and 9.3% missing. The global ranking is similar across age-groups but with age-specific differences. The proportion of missing was around 3-times lower than in the other Italian published population-based series and similar to the SEER one. In Italy, are estimated 38,841 HR+\u2009\/HER2- breast cancer cases, 4665 HR+\u2009\/HER2+\u2009, 4098 HR-\/HER2-, 2281 HR-\/HER2+\u2009, and 5092 not specified. Numbers by age-group were provided.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The present estimates relied on high-quality population-based data and provide a clinically relevant information on the burden of breast cancer subtypes. These data will support the planning of therapy needs for oncologists, decision-makers, and all other stakeholders.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-023-04593-6","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T19:03:21Z","timestamp":1678907001000},"page":"7299-7304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Female breast cancer subtypes in the Romagna Unit of the Emilia-Romagna cancer registry, and estimated incident cases by subtypes and age in Italy in 2020"],"prefix":"10.1007","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4649-2034","authenticated-orcid":false,"given":"Emanuele","family":"Crocetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Ravaioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orietta","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauro","family":"Bucchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Vattiato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Balducci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Baldacchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Falcini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"4593_CR1","unstructured":"AIOM (2021a), Registri Tumori Italiani, Siapec, Fondazione Aiom, Passi, Passi d\u2019Argento, ONS. I numeri del cancro in Italia, 2021a. Intermedia Editore, Brescia, Italy. https:\/\/www.aiom.it\/wp-content\/uploads\/2021\/11\/2021_NDC.pdf"},{"key":"4593_CR2","unstructured":"AIOM (2021b). Linee guida Neoplasie della mammella. Edizione 2021b, aggiornata a 11.11.2021 (https:\/\/www.aiom.it\/linee-guida-aiom-2021-neoplasie-della-mammella\/. Accessed 9th July 2022"},{"key":"4593_CR3","unstructured":"AIOM-Airtum (2018) I numeri del cancro in Italia, 2018. Intermedia Editore, Rodengo Saiano (BS), Italy. https:\/\/www.registri-tumori.it\/cms\/pubblicazioni\/i-numeri-del-cancro-italia-2018. Accessed 9th July 2022"},{"key":"4593_CR4","unstructured":"AIOM-Airtum (2019) I numeri del cancro in Italia, 2019. Intermedia Editore, Rodengo Saiano (BS), Italy. https:\/\/www.registri-tumori.it\/cms\/pubblicazioni\/i-numeri-del-cancro-italia-2019. Accessed 9 July 2022"},{"key":"4593_CR5","unstructured":"AIOM-Airtum (2020) I numeri del cancro in Italia, 2020. Intermedia Editore, Rodengo Saiano (BS), Italy. https:\/\/www.registri-tumori.it\/cms\/pubblicazioni\/i-numeri-del-cancro-italia-2020. Accessed 9 July 2022"},{"issue":"4-5Suppl 1","key":"4593_CR6","first-page":"1","volume":"37","author":"Airtum","year":"2013","unstructured":"Airtum (2013) Italian cancer figures, report 2013. Multiple tumours. Epidemiol Prev 37(4-5Suppl 1):1\u2013152","journal-title":"Epidemiol Prev"},{"key":"4593_CR7","unstructured":"Andreano A, Buzzoni C, Guzzinati S, Russo AG (2019). I tumori in Italia - TREND 2003\u20132014, Airtum, https:\/\/www.registri-tumori.it\/cms\/sites\/default\/files\/pubblicazioni\/MONOGRAFIA_TREND_2003_2014.pdf. Accessed 09 July 2022"},{"key":"4593_CR8","unstructured":"Bray F, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Zanetti R and Ferlay J, editors (2017) Cancer Incidence in Five Continents, Vol. XI (electronic version). Lyon: International Agency for Research on Cancer. https:\/\/ci5.iarc.fr. Accessed 9 July 2022"},{"key":"4593_CR9","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.1007\/s00330-019-06050-w","volume":"29","author":"L Bucchi","year":"2019","unstructured":"Bucchi L, Ravaioli A, Baldacchini F, Giuliani O, Mancini S, Vattiato R, Falcini F, Giorgi Rossi P, Campari C, Canuti D, Di Felice E, Sassoli de Bianchi P, Ferretti S, Bertozzi N, Emilia-Romagna Region Workgroup for Mammography Screening Evaluation (2019) Annual mammography at age 45\u201349 years and biennial mammography at age 50\u201369 years: comparing performance measures in an organised screening setting. Eur Radiol 29:5517\u20135527. https:\/\/doi.org\/10.1007\/s00330-019-06050-w","journal-title":"Eur Radiol"},{"key":"4593_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/0969141320946059","volume":"28","author":"L Bucchi","year":"2021","unstructured":"Bucchi L, Ravaioli A, Baldacchini F, Giuliani O, Mancini S, Vattiato R, de Bianchi PS, Ferretti S, Falcini F (2021) Incidence of interval breast cancer among women aged 45\u201349 in an organised mammography screening setting. J Med Screen 28:207\u2013209. https:\/\/doi.org\/10.1177\/0969141320946059","journal-title":"J Med Screen"},{"key":"4593_CR11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s12253-011-9381-z","volume":"17","author":"A Caldarella","year":"2011","unstructured":"Caldarella A, Crocetti E, Bianchi S, Vezzosi V, Urso C, Biancalani M, Zappa M (2011) Female breast cancer status according to ER, PR and HER2 expression: a population based analysis. Pathol Oncol Res 17:753\u2013758. https:\/\/doi.org\/10.1007\/s12253-011-9381-z","journal-title":"Pathol Oncol Res"},{"key":"4593_CR12","unstructured":"ENCR Recommendations for a Standard Dataset for the European Network of Cancer Registries. https:\/\/www.encr.eu\/sites\/default\/files\/pdf\/recommendations.pdf. Accessed 9th July 2022"},{"key":"4593_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10549-018-4899-3","volume":"172","author":"G Farshid","year":"2018","unstructured":"Farshid G, Walters D (2018) Molecular subtypes of screen-detected breast cancer. Breast Cancer Res Treat 172:191\u2013199. https:\/\/doi.org\/10.1007\/s10549-018-4899-3","journal-title":"Breast Cancer Res Treat"},{"key":"4593_CR14","unstructured":"Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. https:\/\/gco.iarc.fr\/today. Accessed 09 July 2022"},{"key":"4593_CR15","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.3390\/ijerph17114165","volume":"17","author":"P Giorgi Rossi","year":"2020","unstructured":"Giorgi Rossi P, Djuric O, Navarra S, Rossi A, Di Napoli A, Frova L, Petrelli A (2020) Geographic inequalities in breast cancer in italy: trend analysis of mortality and risk factors. Int J Environ Res Public Health 17:4165. https:\/\/doi.org\/10.3390\/ijerph17114165","journal-title":"Int J Environ Res Public Health"},{"key":"4593_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10549-016-3895-8","volume":"158","author":"O Giuliani","year":"2016","unstructured":"Giuliani O, Mancini S, Puliti D, Caranci N, Ravaioli A, Vattiato R, Palumbo M, Colamartini A, Biggeri A, Bucchi L, Amadori D, Falcini F (2016) Patterns and determinants of receipt of follow-up mammography and\/or clinical examination in a cohort of Italian breast cancer survivors. Breast Cancer Res Treat 158:543\u2013551. https:\/\/doi.org\/10.1007\/s10549-016-3895-8","journal-title":"Breast Cancer Res Treat"},{"key":"4593_CR17","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Th\u00fcrlimann B, Senn H-J (2013) Personalizing the treatment of women with early breast cancer: highlights of the St gallen international expert consensus on the primary therapy of early breast cancer consensus on the primary therapy of early breast cancer 2013. Ann Oncol 24:2206\u20132223. https:\/\/doi.org\/10.1093\/annonc\/mdt303","journal-title":"Ann Oncol"},{"key":"4593_CR18","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn H-J, Panel member (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736\u20131747. https:\/\/doi.org\/10.1093\/annonc\/mdr304","journal-title":"Ann Oncol"},{"key":"4593_CR19","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1093\/annonc\/mds586","volume":"23","author":"S Guiu","year":"2012","unstructured":"Guiu S, Michiels S, Andr\u00e9 F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, Van de Vijver M, Viale G, Loi S, Reis-Filho JS (2012) Molecular subclasses of breast cancer: how do we define them? The IMPAKT working group statement. Ann Oncol 23:2997\u20133006. https:\/\/doi.org\/10.1093\/annonc\/mds586","journal-title":"Ann Oncol"},{"key":"4593_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/jnci\/dju055","volume":"28","author":"N Howlader","year":"2014","unstructured":"Howlader N, Altekruse SF, Li CI, Chen CW, Clarke CA, Ries LAG, Cronin KA (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. JNCI 28:106. https:\/\/doi.org\/10.1093\/jnci\/dju055","journal-title":"JNCI"},{"key":"4593_CR21","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1158\/1055-9965","volume":"27","author":"N Howlader","year":"2018","unstructured":"Howlader N, Cronin KA, Kurian AW, Andridge R (2018) Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev 27:619\u2013626. https:\/\/doi.org\/10.1158\/1055-9965","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"4593_CR22","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/ijc.31950","volume":"144","author":"ALV Johansson","year":"2019","unstructured":"Johansson ALV, Trewin CB, Hjerkind KV, Ellingjord-Dale M, B\u00f8rge Johannesen T, Ursin G (2019) Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort. Int J Cancer 144(6):1251\u20131261. https:\/\/doi.org\/10.1002\/ijc.31950","journal-title":"Int J Cancer"},{"key":"4593_CR23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ejca.2017.07.015","volume":"84","author":"P Minicozzi","year":"2017","unstructured":"Minicozzi P, Innos K, Sanchez MJ, Trama A, Walsh PM, Marcos-Gragera R, Dimitrova N, Botta L, Visser O, Rossi S, Tavilla A, Sant M, The EUROCARE-5 Working Group (2017) Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: a EUROCARE-5 study. Eur J Cancer 84:335\u2013353. https:\/\/doi.org\/10.1016\/j.ejca.2017.07.015","journal-title":"Eur J Cancer"},{"key":"4593_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2015.11.010","volume":"43","author":"A Musolino","year":"2016","unstructured":"Musolino A, Boggiani D, Sikokis A, Rimanti A, Pellegrino B, Vattiato R, Sgargi P, Falcini F, Caminiti C, Michiara M, Leonardi F (2016) Prognostic risk factors for treatment decision in pT1a, b N0M0 HER2-positive breast cancers. Cancer Treat Rev 43:1\u20137. https:\/\/doi.org\/10.1016\/j.ctrv.2015.11.010","journal-title":"Cancer Treat Rev"},{"key":"4593_CR25","unstructured":"ONS Osservatorio Nazionale Screening, Rapporto 2022. https:\/\/www.osservatorionazionalescreening.it\/content\/rapporto-ons-2020. Accessed 01 Dec 2022"},{"key":"4593_CR26","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, L\u00f8nning PE, B\u00f8rresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747\u2013752. https:\/\/doi.org\/10.1038\/35021093","journal-title":"Nature"},{"key":"4593_CR27","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s10549-017-4535-7","volume":"167","author":"A Ravaioli","year":"2018","unstructured":"Ravaioli A, Falcini F, Bucchi L (2018) Hormone receptor-positive invasive lobular and ductal carcinoma of the breast have comparable hormone receptor expression levels both if detected by screening and clinically. Breast Cancer Res Treat 167:817\u2013818. https:\/\/doi.org\/10.1007\/s10549-017-4535-7","journal-title":"Breast Cancer Res Treat"},{"key":"4593_CR28","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.3390\/jcm10245873","volume":"10","author":"G Tagliabue","year":"2021","unstructured":"Tagliabue G, Fabiano S, Contiero P, Barigelletti G, Castelli M, Mazzoleni G, Boschetti L, Fanetti AC, Puppo A, Musolino A, Cirilli C, Seghini P, Mangone L, Caldarella A, Lotti F, Mazzucco W, Benedetto A, Dinaro YM, Sferrazza A, Pinna P, Perotti V, AIRTUM Working Group (2021) Molecular subtypes, metastatic pattern and patient age in breast cancer: an analysis of italian network of cancer registries (AIRTUM) data. J Clin Med 10:5873. https:\/\/doi.org\/10.3390\/jcm10245873","journal-title":"J Clin Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04593-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04593-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04593-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T17:31:36Z","timestamp":1690479096000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04593-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["4593"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04593-6","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"assertion":[{"value":"5 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Ethics Committee at the Romagna Cancer Institute (ID: IRST100.37).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}